Financial Ratios

NOVELIX PHARMACEUTICALS LTD.

NSE : NABSE : 536565ISIN CODE : INE314I01036Industry : TradingHouse : Private
BSE62.56-1.19 (-1.87 %)
PREV CLOSE ( ) 63.75
OPEN PRICE ( ) 58.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 11607
TODAY'S LOW / HIGH ( )58.00 68.69
52 WK LOW / HIGH ( ) 25.3570.16
NSE
This Company is not listed in NSE
Select year
ParticularsMar2025Mar2024Mar2023Mar2022Mar2021
Operational & Financial Ratios
   Earnings Per Share (Rs)0.080.01-0.07-1.93-4.04
   CEPS(Rs)0.120.060.00-1.84-3.93
   DPS(Rs)0.000.000.000.000.00
   Book NAV/Share(Rs)17.639.088.888.9410.87
   Tax Rate(%)31.4851.02-2.490.350.07
Margin Ratios
   Core EBITDA Margin(%)0.48-5.84-36.86-242.62-348.58
   EBIT Margin(%)0.400.53-4.14-185.69-324.81
   Pre Tax Margin(%)0.400.50-4.16-185.70-324.88
   PAT Margin (%)0.280.25-4.27-185.05-324.66
   Cash Profit Margin (%)0.401.15-0.26-176.55-316.25
Performance Ratios
   ROA(%)0.490.14-0.83-19.56-31.42
   ROE(%)0.680.14-0.83-19.45-31.32
   ROCE(%)1.000.31-0.81-19.51-31.33
   Asset Turnover(x)1.780.580.200.110.10
   Sales/Fixed Asset(x)20.932.970.980.340.28
   Working Capital/Sales(x)1.781.030.340.180.22
Efficiency Ratios
   Fixed Capital/Sales(x)0.050.341.022.973.55
   Receivable days107.838.8137.7140.0029.83
   Inventory Days12.1187.06175.73168.8559.18
   Payable days57.422.7014.523.78
Valuation Parameters
   PER(x)313.431332.560.000.000.00
   PCE(x)216.12286.73-1963.90-4.84-1.72
   Price/Book(x)1.511.891.010.990.62
   Yield(%)0.000.000.000.000.00
   EV/Net Sales(x)0.843.274.995.453.71
   EV/Core EBITDA(x)159.27227.43-3528.80-3.08-1.17
   EV/EBIT(x)208.07612.05-120.52-2.94-1.14
   EV/CE(x)1.471.880.980.640.43
   M Cap / Sales0.863.305.198.545.44
Growth Ratio
   Net Sales Growth(%)627.27200.7266.58-16.25-2.47
   Core EBITDA Growth(%)166.833153.6299.8753.10-1817.36
   EBIT Growth(%)449.67138.7596.2852.12-3149.46
   PAT Growth(%)711.76117.3796.1652.27-3546.25
   EPS Growth(%)558.14117.4496.1652.27-3546.14
Financial Stability Ratios
   Total Debt/Equity(x)0.000.000.000.000.00
   Current Ratio(x)2.79407.4468.83568.35194.19
   Quick Ratio(x)2.70289.6055.52503.09183.93
   Interest Cover(x)192.2317.35-215.580.00-4671.71
   Total Debt/Mcap(x)0.000.000.000.000.00

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.